Theme

The Fractured Pathway

Source
Источник: Обзор пути пациента с остеопорозом в России, включая данные клинических рекомендаций 2023 года.

Diagnostic Bottlenecks, High Dropout Rates, and the Regional Divide in Osteoporosis Biological Therapy

15%
On-Time DXA Diagnostics

Only 15% of patients receive the "gold standard" densitometry on time, creating a systemic bottleneck that forces reactive treatment—often only after a catastrophic fracture.

Clinical Pathway Architecture

Patient Group Treatment Regimen Duration
Cohort A: First-Line
Standard Therapy		 Bisphosphonates
+ Calcium / Vit D		 1–2 Years
Cohort B: High-Risk
FRAX > 20% or Non-Responders		 Denosumab / Teriparatide
(Biological Therapy)		 18–24 Mo.
(or 6-mo inj)
Goal: Stable T-score & No Fractures Risk: Hypercalcemia & Intolerance

Key Journey Breakdowns

The Silent Dropout

An alarming 40% of patients abandon first-line bisphosphonates because internal bone remodeling lacks immediate obvious effects.

Severe Regional Disparities

Specialist shortages and medical consilium delays mean regional patients wait up to 1.5 years to access life-changing biologics compared to Moscow.

Diagnostic Wait Barrier

DXA scanning suffers from a severe backlog, keeping crucial targeted treatments out of reach for 3 to 6 months in regional queues.

Recommendation: Shift to Proactive Management

1. Decentralize Diagnostics
Leverage telemedicine for specialist reviews and decentralize DXA access to aggressively cut the initial 3–6 month delay.
2. Implement Adherence Tracking
Counter the 40% dropout rate via targeted patient education in Year 1, explaining that "invisible" bone remodeling prevents future fractures.
3. Fast-Track Biologicals
Standardize "fast-track" criteria (FRAX > 20%) to safely bypass prolonged regional medical consortium approvals for high-risk profiles.
AbbreviationsQuick
ИМТ — индекс массы тела; ОМС — обязательное медицинское страхование; DXA — двухэнергетическая рентгеновская абсорбциометрия (денситометрия); FRAX — алгоритм оценки риска переломов; P1NP — маркер костного метаболизма.
Bibliography1
  1. Клинические рекомендации по остеопорозу (2023).